ZEB1 and familial pancreatic carcinoma: Meidhof et al. 39 reported that Mocetinostat reversed the gemcitabine resistance in pancreatic cancer via suppressing the EMT TF ZEB1. However, based on our results, Mocetinostat increased ZEB1 expression significantly in epithelial-like lines PEO1 and OVCA429, correlating with increased resistance to HDACi treatment.